期刊文献+

转鲑鱼降钙素基因酵母及RANKL对大鼠血管平滑肌细胞体外钙化的影响

The Effect of Salmon Calcitonin Gene Transformed Yeast and RANKL on Calcification of Rat Aortic Vascular Smooth Muscle Cells in vitro
下载PDF
导出
摘要 观察核因子kB受体激活物配体(RANKL)对大鼠血管平滑肌细胞体外钙化的调节作用,以及转鲑鱼降钙素基因酵母对RANKL调节作用的影响。体外培养大鼠血管平滑肌细胞,建立体外血管平滑肌细胞钙化模型,在培养介质中分别加入RANKL及转鲑鱼降钙素基因酵母蛋白上清液,观察细胞钙沉积、细胞碱性磷酸酶活性及骨钙素的变化情况。结果表明,RANKL促进钙化培养的大鼠血管平滑肌细胞的钙沉积、细胞碱性磷酸酶活性及骨钙素的表达,而转鲑鱼降钙素基因酵母能够抑制RANKL的促钙化作用。RANKL可能通过增加细胞碱性磷酸酶活性及骨钙素的表达从而促进血管平滑肌细胞向成骨细胞转化;转鲑鱼降钙素基因酵母可能通过OPG/RANKL/RANK途径抑制血管平滑肌细胞钙化。 To investigate the regulative effect of Receptor Activator of Nuclear Factor-kappa B Ligand(RAN- KL) on calcification of rat aortic v'ascular smooth muscle cells(VSMC) in vitro, and the influence of salmon calcitonin transformed yeast (yAGA2-sCT) on RANKL. Results showed that Culture of rat aortic vascular smooth muscle cells(VSMCs) in vitro and establishment of a calcification model, RANKL and yAGA2-sCT were added into the culture media, the calcium deposition, alkaline phosphatase(AKP) activity, and alterations of expression of osteocalcin were examined. Results showed that RANKL promoted the calcium deposition, AKP activity, and the expression of osteocalcin in VSMC, whereas yAGA2-sCT inhibited the effects of RANKL. RANKL increased calcium deposition in VSMCs, possibly through increasing AKP activity and expression of osteocalcium and thus favored the transformation of VSMC to osteoblast, and yAGA2-sCT may inhibit VSMC calcification through the OPG/RANKL/RANK system.
出处 《中国海洋大学学报(自然科学版)》 CAS CSCD 北大核心 2009年第6期1241-1245,共5页 Periodical of Ocean University of China
基金 国家高技术研究发展计划项目(819-04-10)资助
关键词 钙化 血管平滑肌细胞 RANKL 转鲑鱼降钙素基因酵母 calcification vascular smooth muscle cells(VSMC) RANKL yAGA2-sCT
  • 相关文献

参考文献23

  • 1Iribarren C, Sidney S, Sternfeld B, et al. Calcification of theaortic arch: risk factor and association with coronary heart disease, stroke, and peripheral vascular disease [J]. JAMA, 2000, 88: 26-33.
  • 2Christian R C, Fitzpatrick L A. Vascular calcification [J]. Curr Opin Nephrol Hypertens, 1999, 8(4) : 443-448.
  • 3Farzaneh F A, Proudfoot D, Shanahan C, et al. Vascular and valvar calcification: recent advances [J]. Heart, 2001, 85: 13-17.
  • 4Burnett J R, Vasikaran S D. Cardiovascular disease and osteoporosis: Is there a link between lipids and Bone? [ J ]. AnnClin Biochem, 2002, 39(Pt 3) : 203- 210.
  • 5Lorenz, Shui, Riggs, et al. Effects of immunosuppressants on receptor activator of NF-kappa B ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells [ J ]. Biochem Biophys Res Commun, 2001, 280: 334-339.
  • 6Hofbauer L C, Sehoppet M. Osteoprotegerin: a link between osteoporosis and arterial calcification [ J ] ? LANCET, 2001, 358 : 257-259.
  • 7Simonet W S, Lacey D L, Dunstan C R, et al. Osteoprotegerin: a novel secreted protein involved in the regulation of bone density [J ]. Ceil, 1997, 89: 309-319.
  • 8Min H, Morony S, Sarosi I, et al. Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis [J]. J Exp Med, 2000, 192: 463-474.
  • 9Bucay N, Sarosi I, Dunstan C R, et al. Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification [ J ]. Gene Dev, 1998, 12: 1260-1268.
  • 10Khosla S. Minireview: The OPG/RANKL/RANK System [J]. Endocrinology, 2001, 142(12) : 5050-5055.

共引文献3

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部